Previous Close | 0.2200 |
Open | 0.2500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 65.00 |
Expire Date | 2023-01-20 |
Day's Range | 0.2100 - 0.2500 |
Contract Range | N/A |
Volume | |
Open Interest | 25.34k |
Novavax missed Wall Street expectations but remains optimistic about the fourth quarter and 2023.
Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.
Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.